# Palbociclib After CDK and Endocrine Therapy (PACE)

> **NCT03147287** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 220 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03147287
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03147287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03147287, "Palbociclib After CDK and Endocrine Therapy (PACE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03147287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*